4.4 Review

Understanding melatonin receptor pharmacology: Latest insights from mouse models, and their relevance to human disease

Journal

BIOESSAYS
Volume 36, Issue 8, Pages 778-787

Publisher

WILEY
DOI: 10.1002/bies.201400017

Keywords

circadian rhythm; diabetes; melatonin; melatonin receptors; photoperiodism; retina; sleep

Funding

  1. National Institutes of Health [NS43459, EY028821, EY022216]
  2. INSERM
  3. CNRS
  4. Who am I? laboratory of excellence - French government through Investments for the Future program [ANR-11-LABX-0071, ANR-11-IDEX-0005-01]
  5. Who am I? laboratory of excellence - French government through Investments for the Future program [Fondation Recherche Medicale] [FRM DEQ20130326503]
  6. CODDIM [(Region Ile-de-France)]
  7. [5U54NS060659]
  8. [S21MD000101]
  9. [G12-RR03034]
  10. [U54RR026137]
  11. [T32 HL103104]

Ask authors/readers for more resources

Melatonin, the neuro-hormone synthesized during the night, has recently seen an unexpected extension of its functional implications toward type 2 diabetes development, visual functions, sleep disturbances, and depression. Transgenic mouse models were instrumental for the establishment of the link between melatonin and these major human diseases. Most of the actions of melatonin are mediated by two types of G protein-coupled receptors, named MT1 and MT2, which are expressed in many different organs and tissues. Understanding the pharmacology and function of mouse MT1 and MT2 receptors, including MT1/MT2 heteromers, will be of crucial importance to evaluate the relevance of these mouse models for future therapeutic developments. This review will critically discuss these aspects, and give some perspectives including the generation of new mouse models.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available